Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 8
2004 15
2005 20
2006 16
2007 13
2008 13
2009 22
2010 25
2011 35
2012 45
2013 37
2014 33
2015 34
2016 34
2017 43
2018 51
2019 54
2020 70
2021 60
2022 41
2023 24
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

604 results

Results by year

Filters applied: . Clear all
Page 1
Active and passive smoking and breast cancer in Japan: a pooled analysis of nine population-based cohort studies.
Wada K, Nagata C, Utada M, Sakata R, Kimura T, Tamakoshi A, Sugawara Y, Tsuji I, Sato R, Sawada N, Tsugane S, Oze I, Ito H, Kitamura T, Koyanagi YN, Lin Y, Matsuo K, Abe SK, Inoue M; Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Wada K, et al. Int J Epidemiol. 2024 Apr 11;53(3):dyae047. doi: 10.1093/ije/dyae047. Int J Epidemiol. 2024. PMID: 38604675
Evaluation of the performance of both machine learning models using PET and CT radiomics for predicting recurrence following lung stereotactic body radiation therapy: A single-institutional study.
Nemoto H, Saito M, Satoh Y, Komiyama T, Marino K, Aoki S, Suzuki H, Sano N, Nonaka H, Watanabe H, Funayama S, Onishi H. Nemoto H, et al. Among authors: suzuki h. J Appl Clin Med Phys. 2024 Mar 4:e14322. doi: 10.1002/acm2.14322. Online ahead of print. J Appl Clin Med Phys. 2024. PMID: 38436611
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study.
Matsumoto K, Shiroyama T, Tamiya M, Minami T, Kinehara Y, Tamiya A, Suga Y, Kuge T, Mori M, Suzuki H, Tobita S, Ueno K, Namba Y, Tetsumoto S, Niki T, Morimura O, Osa A, Nishino K, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A. Matsumoto K, et al. Among authors: suzuki h. Cancer Immunol Immunother. 2024 Jan 4;73(1):4. doi: 10.1007/s00262-023-03583-4. Cancer Immunol Immunother. 2024. PMID: 38175294 Free PMC article.
Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: suzuki h. Lung Cancer. 2024 Feb;188:107450. doi: 10.1016/j.lungcan.2023.107450. Epub 2023 Dec 30. Lung Cancer. 2024. PMID: 38160082 No abstract available.
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: suzuki h. Lung Cancer. 2023 Dec;186:107426. doi: 10.1016/j.lungcan.2023.107426. Epub 2023 Nov 19. Lung Cancer. 2023. PMID: 37992594
604 results